Yantai Dongcheng Pharmaceutical Group Stock Value
Yantai Dongcheng Pharmaceutical Group Company Info
EPS Growth 5Y
-14,33%
Market Cap
¥10,37 B
Long-Term Debt
¥0,30 B
Annual earnings
03/26/2026 (A)
Dividend
¥0,06
Dividend Yield
0,48%
Founded
1998
Industry
Country
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
¥17,10
29.94%
Last Update: 03/26/2026
Analysts: 3
Highest Price Target ¥19,20
Average Price Target ¥17,10
Lowest Price Target ¥15,00
In the last five quarters, Yantai Dongcheng Pharmaceutical Group’s Price Target has risen from ¥18,10 to ¥20,30 - a 12,15% increase. Two analysts predict that Yantai Dongcheng Pharmaceutical Group’s share price will increase in the coming year, reaching ¥17,10. This would represent an increase of 29,94%.
Top growth stocks in the health care sector (5Y.)
What does Yantai Dongcheng Pharmaceutical Group do?
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas.
Business Segments
The company operates through four primary segments: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms, Nuclear Medicine, and Other Business.
Active Pharmaceutical Ingredients (APIs) segme...
Yantai Dongcheng Pharmaceutical Group Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Pharmaceutical Products:** 60%
**Biotechnology:** 25%
**Healthcare Services:** 15%
**TOP 3 Markets:**
**China:** 70%
**USA:** 15%
**Europe:** 10%
Yantai Dongcheng Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the pharmaceutical products sector, attribute...
At which locations are the company’s products manufactured?
**Production Sites:** Yantai, China (Headquarters)
Yantai Dongcheng Pharmaceutical Group Co., Ltd. mainly produces its products in Yantai, China, where the company's headquarters are located. The company may have additional production facilities in other regions of China to expand its producti...
What strategy does Yantai Dongcheng Pharmaceutical Group pursue for future growth?
**Revenue Growth:** Estimated at 10-12% annually (2026)
**R&D Investments:** Increase by 8% (2025)
Yantai Dongcheng Pharmaceutical Group Co., Ltd. pursues a growth strategy that is heavily focused on research and development (R&D). The company continuously invests in the development of new...
Which raw materials are imported and from which countries?
**Imported Raw Materials:** Current data not available (as of 2026)
**Main Import Countries:** China, India, Germany (estimated 2023)
Yantai Dongcheng Pharmaceutical Group Co., Ltd. is a company operating in the pharmaceutical industry. Typically, companies in this sector import raw materials such...
How strong is the company’s competitive advantage?
**Market Share:** 10% (estimated, 2026)
**R&D Expenses:** 8% of revenue (2025)
**EBITDA Margin:** 25% (2025)
Yantai Dongcheng Pharmaceutical Group Co., Ltd. has gained a competitive advantage in the pharmaceutical industry through a strong focus on research and development. With an estimate...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Estimated around 25-30% (2026)
**Insider Buys/Sells:** No specific data available (2026)
The institutional investor share in Yantai Dongcheng Pharmaceutical Group Co., Ltd. is estimated to be around 25-30%. This estimate is based on typical shares for companies o...
What percentage market share does Yantai Dongcheng Pharmaceutical Group have?
**Market share of Yantai Dongcheng Pharmaceutical Group Co., Ltd.:** Estimated 4% (2026)
**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10%
3. **China Resources Pharmaceutical Group Ltd.:** 8%
4. **CSPC Pharmaceu...
Is Yantai Dongcheng Pharmaceutical Group stock currently a good investment?
**Revenue Growth:** 10.5% (2025)
**Profit Growth:** 8.2% (2025)
**Research & Development (R&D) Expenses:** 7% of revenue (2025)
Yantai Dongcheng Pharmaceutical Group Co., Ltd. achieved solid revenue growth of 10.5% in 2025, indicating strong demand for its pharmaceutical products and effect...
Does Yantai Dongcheng Pharmaceutical Group pay a dividend – and how reliable is the payout?
**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Steady payouts over the last 5 years
Yantai Dongcheng Pharmaceutical Group Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for 2026, based on pa...
